DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease..

DS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL.

DS-3032b is a potent, selective, orally available MDM2-p53 inhibitor with potential antineoplastic activity.

DS-437 is a potent, selective, dual inhibitor of PRMT5 and PRMT7 with IC50 of 6.0 uM for both, DS-437 is inactive against 29 other human protein-, DNA-, and RNA-methyltransferases.

DS-6930 (DS 6930, DS6930) is a novel potent, selective PPARγ agonist with EC50 of 41 nM, Emax-68%; significantly recruits several cofactors, such as RIP140 and PGC1, in cofactor recruitment assays; demonstrateshigh PPARγ agonist potency with robust plasma glucose reduction, maintains diminished PPARγ-related adverse effects upon toxicological evaluation in vivo, and demonstrated no hepatotoxicity.

DS-6930b (DS-6930 calcium salt) is the calcium salt of DS-6930, which is a novel potent, selective PPARγ agonist with EC50 of 41 nM, Emax-68%.

DS-70 (α4 integrin inhibitor DS-70) is a novel potent α/β- peptidomimetic antagonist of α4 integrin, binds to integrin α4β1 with nanomolar affinity.

DS-7423 is a novel potent, small-molecule dual inhibitor of PI3K/mTOR with IC50 of 15.6, 1143, 249, 262 and 34.9 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR  respectively.

DS-8500a (DS8500a) is a novel potent, selective, orally available GPR119 agonist with EC50 of 51.5 nM in human GPR119-expressing CHO-K1 cells, displays no significant effect on 66 receptors, channels, or transporters.

DS86760016 is a novel selective bacterial leucyl-tRNA synthetase (LeuRS) inhibitor with IC50 of 0.38 uM (Escherichia coli, LeuRS).

DS88790512 is a potent, selective, and orally bioavailable blocker with IC50 of 11 nM, exhibits excellent selectivity against hERG and hNaV1.5 channels (IC50 >100 uM)..

DS88790512 is a potent, selective, and orally bioavailable blocker with IC50 of 11 nM, exhibits excellent selectivity against hERG and hNaV1.5 channels (IC50 >100 uM)..

Ds-HAPP is an anthrancenyl and dansyl fluorophore ligand.

DSP-0565 (DSP0565) is a new drug candidate with broad anti-convulsant activity, does not bind to any GABA-A binding sites, may be caused as the result of its GABAergic function via novel target..

DSP-1053 is a novel potent serotonin reuptake (SERT) inhibitor with 5-HT1A partial agonistic activity that binds to human serotonin transporter and 5-HT1A receptor with Ki of 1.02 and 5.05 nM, respectively.

DSP-6952 is a novel potent, selective, orally active 5-HT4 receptor partial agonist with Ki of 50-100 nM for human 5-HT4a/4b/4c.

DT204 (DT-204) is a novel SCFSkp2 inhibitor that reduces Skp2 binding to Cullin-1 and Commd1, synergistically enhances BTZ-induced apoptosis.

dTRIM24 is a potent TRIM24 bromodomain inhibitor with IC50 of 217.8 nM (TRIM24 ligand displacement).

Dual BRM and BRG1 inhibitor 14 is a potent, orally active inhibitor of Brahma Homolog (BRM)/SMARCA2 and Brahma-related gene 1 (BRG1) with IC50 of <5 nM for both.

Dual DDR1 and DDR2 inhibitor 5n is a highly potent, selective, dual Discoidin domain receptor DDR1 and DDR2 inhibitor with Kd of 7.9 and 8.0 nM, IC50 of 9.4 and 20.4 nM, repectively.

Duloxetine is a serotonin-norepinephrine reuptake inhibitor with Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).

Duocarmycin TM is an exceptionally potent antitumor antibiotic.